Medarex's Cancer Treatment Shows Promise


Medarex Inc. (Nasdaq: MEDX) indicated that its prostate cancer treatment showed promise sending the stock price up $1.17 to $8.53.


About this Entry

This page contains a single entry by published on June 22, 2009 10:52 AM.

Ontario Securities Commission Investigates Manulife was the previous entry in this blog.

Level 3 Enters Debt Exchange Agreement is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12